Vanda Pharmaceuticals Stock Beneish M Score

VNDA Stock  USD 4.76  0.06  1.24%   
This module uses fundamental data of Vanda Pharmaceuticals to approximate the value of its Beneish M Score. Vanda Pharmaceuticals M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Vanda Pharmaceuticals Piotroski F Score and Vanda Pharmaceuticals Altman Z Score analysis.
For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.
  
At present, Vanda Pharmaceuticals' Short Term Debt is projected to decrease significantly based on the last few years of reporting. The current year's Net Debt To EBITDA is expected to grow to 12.13, whereas Short and Long Term Debt Total is forecasted to decline to about 9 M. At present, Vanda Pharmaceuticals' Book Value Per Share is projected to increase based on the last few years of reporting. The current year's Free Cash Flow Yield is expected to grow to 0.05, whereas Price To Sales Ratio is forecasted to decline to 1.19.
At this time, it appears that Vanda Pharmaceuticals is a possible manipulator. The earnings manipulation may begin if Vanda Pharmaceuticals' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Vanda Pharmaceuticals executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Vanda Pharmaceuticals' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.05
Beneish M Score - Possible Manipulator
Elasticity of Receivables

1.48

Focus
Asset Quality

3.02

Focus
Expense Coverage

0.87

Focus
Gross Margin Strengs

0.76

Focus
Accruals Factor

0.87

Focus
Depreciation Resistance

1.14

Focus
Net Sales Growth

0.71

Focus
Financial Leverage Condition

1.87

Focus

Vanda Pharmaceuticals Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Vanda Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables35.9 M34.2 M
Sufficiently Up
Slightly volatile
Total Revenue137 M192.6 M
Way Down
Slightly volatile
Total Assets680.9 M648.4 M
Sufficiently Up
Slightly volatile
Total Current Assets230.7 M432.9 M
Way Down
Slightly volatile
Non Current Assets Total226.3 M215.5 M
Sufficiently Up
Slightly volatile
Property Plant Equipment3.5 MM
Fairly Up
Slightly volatile
Depreciation And Amortization2.8 MM
Significantly Down
Very volatile
Selling General Administrative75.8 M122.1 M
Way Down
Slightly volatile
Total Current Liabilities44.2 M87.7 M
Way Down
Slightly volatile
Non Current Liabilities Total29.4 M15.8 M
Way Up
Slightly volatile
Short Term Debt2.5 M2.4 M
Sufficiently Up
Pretty Stable
Short Term Investments151.7 M252.4 M
Way Down
Slightly volatile
Long Term Investments15.2 M17.1 M
Fairly Down
Slightly volatile
Gross Profit Margin0.690.9123
Way Down
Pretty Stable

Vanda Pharmaceuticals Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Vanda Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Vanda Pharmaceuticals in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Vanda Pharmaceuticals' degree of accounting gimmicks and manipulations.

About Vanda Pharmaceuticals Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

2.75 Million

At present, Vanda Pharmaceuticals' Depreciation And Amortization is projected to decrease significantly based on the last few years of reporting.

Vanda Pharmaceuticals Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Vanda Pharmaceuticals. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Net Receivables26.4M30.0M32.5M33.5M34.2M35.9M
Total Revenue227.2M248.2M268.7M254.4M192.6M137.0M
Total Assets483.7M533.5M593.8M634.2M648.4M680.9M
Total Current Assets354.1M409.1M478.3M519.3M432.9M230.7M
Net Debt(32.6M)(47.4M)(42.0M)(123.9M)(126.4M)(120.1M)
Operating Income22.8M27.2M42.2M6.3M(14.0M)(14.6M)
Investments(67.3M)(39.7M)(76.1M)50.6M107.2M112.5M

About Vanda Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vanda Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vanda Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vanda Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vanda Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vanda Pharmaceuticals' short interest history, or implied volatility extrapolated from Vanda Pharmaceuticals options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Vanda Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vanda Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vanda Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vanda Pharmaceuticals Stock:
Check out Vanda Pharmaceuticals Piotroski F Score and Vanda Pharmaceuticals Altman Z Score analysis.
For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.
Note that the Vanda Pharmaceuticals information on this page should be used as a complementary analysis to other Vanda Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Vanda Stock analysis

When running Vanda Pharmaceuticals' price analysis, check to measure Vanda Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vanda Pharmaceuticals is operating at the current time. Most of Vanda Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vanda Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vanda Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vanda Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Is Vanda Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vanda Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.96)
Earnings Share
0.04
Revenue Per Share
3.357
Quarterly Revenue Growth
(0.30)
Return On Assets
(0.01)
The market value of Vanda Pharmaceuticals is measured differently than its book value, which is the value of Vanda that is recorded on the company's balance sheet. Investors also form their own opinion of Vanda Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vanda Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vanda Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vanda Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vanda Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.